[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338808-105":59,"doc-detail-338808-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-the-activin-receptor-1c-on-cd4-t-cells-for-cancer-immunotherapy","Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy","","Activins are TGF-β superfamily proteins with limited immune-endocrine characterization in cancers. The study shows tumor-bearing mice with elevated systemic activin levels correlating with tumor burden, alongside increased patient plasma activin versus healthy controls. Both tumor and immune cells contribute activin. In vitro, activins drive naïve CD4+ differentiation into Foxp3-expressing induced regulatory T cells when TGF-β is constrained, linked to unique Treg expression of activin receptor 1c (ActRIC) and strong ActRIC/ActRIIB induction during iTreg differentiation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-activin-receptor-1c-on-cd4-t-cells-for-cancer-immunotherapy/338808/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-activin-receptor-1c-on-cd4-t-cells-for-cancer-immunotherapy/338808.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What relationship was observed between activin levels and cancer progression?","Question",{"text":112,"@type":113},"Tumor-bearing mice showed elevated systemic activin levels that correlated with tumor burden, and cancer patients had higher plasma activin levels than healthy controls.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did activins influence naïve CD4+ T cell differentiation in vitro?",{"text":117,"@type":113},"Activins promoted differentiation of naïve CD4+ cells into Foxp3-expressing induced regulatory T cells, especially when TGF-β was limited in culture.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does ActRIC play in iTreg development and tumor control?",{"text":121,"@type":113},"ActRIC was uniquely expressed on Tregs, both ActRIC and ActRIIB were upregulated during iTreg differentiation, and ActRIC deficiency reduced iTreg generation while ActRIC blockade improved resistance to tumor progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338808,1790489623,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","ONCOIMMUNOLOGY  \n2024, VOL. 13, NO. 1, 2297503 [https://doi.org/10.1080/2162402X.2023.2297503](https://doi.org/10.1080/2162402X.2023.2297503)  \nORIGINAL RESEARCH     \nTargeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy  \nYing Zhenga,b*, Andriana Lebida,b*, Liam Chunga,b, Juan Fua,b, Xiaoxu Wanga,b, Andrea Otrocola,b, Jelani C. Zarifa,b, Hong Yua,b, Nicolas J. Llosaa,b, and Drew M. Pardolla,b  \naBloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA; bDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA  \nABSTRACT  \nActivins, members ofthe TGF-beta superfamily, have been isolated and identified in the endocrine system, but have not been substantially investigated in the context of the immune system and endocrineunrelated cancers. Here, we demonstrated that tumor-bearing mice had elevated systemic activin levels, which correlated directly with tumor burden. Likewise, cancer patients have elevated plasma activin levels compared to healthy controls. We observed that both tumor and immune cells could be sources of activins. Importantly, our in vitro studies suggest that activins promote differentiation of naïve CD4+ cells into Foxp3-expressing induced regulatory T cells (Tregs), particularly when TGF-beta was limited in the culture medium. Database and qRT-PCR analysis of sorted major immune cell subsets in mice revealed that activin receptor 1c (ActRIC) was uniquely expressed on Tregs and that both ActRIC and ActRIIB (activin receptor 2b) were highly upregulated during iTreg differentiation. ActRIC-deficient naïve CD4+ cells were found to be defective in iTreg generation both in vitro and in vivo. Treg suppression assays were also performed, and ActRIC deficiency did not change the function or stability of iTregs. Mice lacking ActRIC or mice treated with monoclonal anti-ActRIC antibody were more resistant to tumor progression than wild-type controls. This phenotype was correlated with reduced expression of Foxp3 in CD4+ cells in the tumor microenvironment. In light of the information presented above, blocking activin-ActRIC signaling is a promising and disease-specific strategy to impede the accumulation of immunosuppressiveiTregs in cancer. Therefore, it is a potential candidate for cancer immunotherapy.  \nARTICLE HISTORY  \nReceived 12 June 2023 Revised 24 November 2023 Accepted 18 December 2023  \nKEYWORDS  \nActivin; cancer immunotherapy; Foxp3; iTregs; TILs; Acvr1c; Alk7  \nIntroduction  \nActivins, which are members of the transforming growth factor-β) (TGF-β)) superfamily of proteins, are potent regulatory factors that play vital roles in tissue fate determination during embryonic development as well as in regulating homeostatic processes in adults. 1–4 Currently, over 45 members ofthe TGF-β superfamily have been identified, among which inhibins and activins have been found to be closely related but have almost directly opposite biological effects in regulating folliclestimulating hormone (FSH) synthesis and secretion.5 Inhibins are dimers ofan α subunit and a β subunit, whereas activins are homo-or heterodimers of two β subunits. These two subunits are tethered by a disulfide bond. 1 Only one isoform of α subunit, but four isoforms of β subunits (βA, βB, βC, and βE) have been identified so far.5–7  \nActivins signal by binding to a heteromeric tetramer composed of two type I receptors (either ActRIC, gene name Acvr1c, also known as Alk7, or ActRIB/Acvr1b/Alk4) and two type II receptors (either ActRIIA/Acvr2a or ActRIIB/ Acvr2b) . 1,8 Initially, activins bind to type II receptors at the cell surface. This binding, in turn, leads to the recruitment and phosphorylation of type I receptors, which then activate  \nintracellular signaling pathways mainly through Smad proteins or alternatively through MAPK. Primarily, it recruits and phosphorylates receptor-regulated Smad ","cbCaitV7o6Go2jP6","https://ap.wps.com/l/cbCaitV7o6Go2jP6","pdf",4061106,12,"English","# Abstract\n# Introduction\n## Activins and TGF-β signaling\n## Receptor biology and Smad/MAPK pathways\n## Regulatory T cells and tumor immune suppression","[{\"question\":\"What relationship was observed between activin levels and cancer progression?\",\"answer\":\"Tumor-bearing mice showed elevated systemic activin levels that correlated with tumor burden, and cancer patients had higher plasma activin levels than healthy controls.\"},{\"question\":\"How did activins influence naïve CD4+ T cell differentiation in vitro?\",\"answer\":\"Activins promoted differentiation of naïve CD4+ cells into Foxp3-expressing induced regulatory T cells, especially when TGF-β was limited in culture.\"},{\"question\":\"What role does ActRIC play in iTreg development and tumor control?\",\"answer\":\"ActRIC was uniquely expressed on Tregs, both ActRIC and ActRIIB were upregulated during iTreg differentiation, and ActRIC deficiency reduced iTreg generation while ActRIC blockade improved resistance to tumor progression.\"}]","Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy | PDF",1790025847,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94da99a388fa2f7c9ee8ed3ed766d899.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9da11008a75859f7872d3006bf7fe4ff.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/423bd0e8b9c38084facabea19a8a8219.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c59cfd0d9bee02dc875a3e25ae88678f.webp",980,1306]